Morten Karsdal received his Ph.D. in Bone and Cartilage Pharmacology from the University of Southern Denmark in 2004. He joined Nordic Bioscience in 2001 and has served as CEO since June 2010. Professor Karsdal has extensive research, pharmacological and biomarker experience in the field of rheumatology (RA & OA), diabetes and fibrosis with more than 350 peer-reviewed publications in top journals. Professor Karsdal has spearheaded the development of FDA approved molecular diagnostics; in excess of 60 commercialized ELISA assays. Utilizing his broad experience in clinical trial design, clinical use of biochemical markers, and the use of biomarkers in translational science, Professor Karsdal has participated in more than 30 clinical studies, and two pivotal phase III clinical studies in OA. He has worked with multiple oral formulations of smaller proteins and has identified and participated in the development of treatments for fibrosis, osteoporosis, osteoarthritis and diabetes, from target identification, preclinical development through phase I to phase III studies. He is Honorary Professor in inflammation research at the University of Southern Denmark, and continues to supervise postgraduate students.